Osbourne says any medicine can be misused and connects Ozempic to the body image struggles he had when he was younger.
Recap by typeshit. Post by Facebook on Facebook.
A one-line stock move for the maker of Mounjaro and Zepbound, with no reason given for the gain.
29:53
Journalist Scott Carney argues in favor of gray-market peptides. Only the title is available, so watch for his full reasoning and treat any health claims with caution.
The company announced exclusive manufacturing rights across its needle-free peptide products. Terms aren't given here.
The endocrinologist says fear, judgment and misinformation still shape how people see GLP-1 drugs, and asks patients to learn before deciding.
A Facebook user explains that compounded GLP-1 versions were allowed during the branded drug shortage and flags what that means for people still using them.
After his appetite disappeared on tirzepatide, Krasno talks with the Your Best Shot author about food and why scale weight can mask muscle, bone and testosterone loss.
Loading…